GRI Bio $GRI Pioneers Breakthrough Therapies For Inflammatory Diseases

Benzinga

GRI BIO (NASDAQ: GRI) is a dynamic clinical-stage biotechnology company at the forefront of revolutionizing healthcare through groundbreaking scientific advancements. The company is focused on fundamentally changing how inflammatory, fibrotic and autoimmune diseases are treated.

Transcript

00:00 (upbeat music)

00:02 GRI Bio, trading on the NASDAQ under the ticker GRI,

00:05 is a dynamic and promising clinical stage

00:08 biotechnology company at the forefront

00:10 of revolutionizing healthcare

00:11 through groundbreaking scientific advancements.

00:14 The company is focused on fundamentally changing

00:16 how inflammatory, fibrotic,

00:18 and autoimmune diseases are treated.

00:20 GRI is led by an expert team of executives

00:22 with years of experience

00:23 leading successful biotech companies.

00:26 The combination of business acumen

00:27 and leading scientific research

00:29 makes GRI's efforts to change

00:30 the inflammatory therapy landscape a reality.

00:33 When the body's immune system is working abnormally,

00:36 it can lead to chronic inflammation

00:38 that is extremely damaging.

00:39 Two of the most recognized inflammatory diseases

00:42 are IPF or idiopathic pulmonary fibrosis and lupus.

00:46 IPF and lupus both represent huge markets

00:49 with unmet needs.

00:51 IPF leads of scouring the lungs,

00:53 which makes breathing difficult and painful.

00:55 There are currently no cures and few treatments.

00:58 It was estimated to be a 3.9 billion market in 2022.

01:02 Lupus is an autoimmune disease

01:04 wherein the body essentially attacks itself.

01:06 Like IPF, treatments are limited

01:08 and plagued by side effects.

01:10 The exciting and novel nature of GRI Bio's approach

01:13 and one that could finally bring relief

01:15 to those suffering from IPF and lupus

01:18 centers around NKT cells,

01:20 which are key regulators earlier

01:22 in the inflammatory cascade.

01:23 Specifically, the type one invariant NKT, INKT,

01:27 cells play a critical role in propagating the injury,

01:31 inflammatory response, and fibrosis observed

01:33 in inflammatory and fibrotic indications.

01:36 GRI Bio is focused on developing therapies

01:39 that inhibit INKT cell activity

01:41 to interrupt disease progression

01:43 and restore homeostasis in the immune system.

01:45 The company has a few big years ahead

01:47 with exciting expected milestones,

01:49 some of which are highlighted as follows.

01:52 In the second half of 2023,

01:53 their lead candidate, GRI0621,

01:56 will begin a phase two A biomarker study.

01:59 The data will be announced in 2024.

02:02 In the first half of 2024,

02:03 the IND-enabled studies for GRI0803 will be complete

02:08 and the company will find for IND.

02:11 By the end of 2024,

02:12 results from phase one A and B will be reported.

02:15 These milestones, along with potential of GRI's library

02:18 of over 500 compounds,

02:20 will add to the company's ability

02:21 to fuel a growing pipeline

02:23 and potentially develop new therapies

02:25 for other inflammatory, fibrotic, and autoimmune diseases.

02:29 [MUSIC PLAYING]

Category

Transcript

Be the first to comment

Recommended